论文部分内容阅读
目的:观察辅酶Q10联合血脂康治疗非酒精性脂肪肝的疗效。方法:将74例脂肪肝患者随机分入治疗组与对照组,治疗组36例给与辅酶Q10联合血脂康治疗6月。对照组38例使用血脂康治疗6月,治疗前后检查各组血清转氨酶、血脂及肝脏CT等并计算体重指数和胰岛素抵抗指数。结果:辅酶Q10联合血脂康治疗组血清转氨酶、胰岛素抵抗指数及血脂改善明显优于对照组,且差异显著。结论:辅酶Q10联合血脂康治疗非酒精性脂肪性肝病患者具有良好作用。
Objective: To observe the efficacy of coenzyme Q10 and Xuezhikang in the treatment of non-alcoholic fatty liver disease. Methods: A total of 74 patients with fatty liver were randomly divided into treatment group and control group. 36 patients in the treatment group were given coenzyme Q10 combined with Xuezhikang for 6 months. In the control group, 38 cases were treated with Xuezhikang for 6 months. Serum transaminases, lipids and liver CT were examined before and after treatment, and body mass index and insulin resistance index were calculated. Results: The serum aminotransferase, insulin resistance index and blood lipids in coenzyme Q10 combined with Xuezhikang treatment group were significantly better than those in control group, and the difference was significant. Conclusion: Coenzyme Q10 combined with Xuezhikang in patients with non-alcoholic fatty liver disease has a good effect.